Mark Emberton

List of Publications by Year
in descending order

271	17,494	34076 52	15249 126
papers	citations	h-index	g-index

276	276	276	10781
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship. European Radiology, 2023, 33, 461-471.	2.3	13
2	Prostate cancer and the human papilloma virus: causative association, role of vaccines, and the impact of the COVID-19 pandemic. Prostate Cancer and Prostatic Diseases, 2022, 25, 55-57.	2.0	6
3	Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial. European Radiology, 2022, 32, 879-889.	2.3	32
4	Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?. British Journal of Radiology, 2022, 95, 20210321.	1.0	5
5	Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score. British Journal of Radiology, 2022, 95, 20210415.	1.0	22
6	Detailing Sexual Outcomes After Focal Therapy for Localised Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 926-941.	1.6	8
7	Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29â€¯MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. Contemporary Clinical Trials, 2022, 112, 106618.	0.8	24
8	Is perfect the enemy of good? Weighing the evidence for biparametric MRI in prostate cancer. British Journal of Radiology, 2022, 95, 20210840.	1.0	1
9	Relationship of prostate cancer topography and tumour conspicuity on multiparametric magnetic resonance imaging: a protocol for a systematic review and meta-analysis. BMJ Open, 2022, 12, e050376.	0.8	2
10	Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study. Diagnostics, 2022, 12, 231.	1.3	5
11	Renal tumouroids: challenges of manufacturing 3D cultures from patient derived primary cells. Journal of Cell Communication and Signaling, 2022, 16, 637-648.	1.8	5
12	Imageâ€Guided Magnetic Thermoseed Navigation and Tumor Ablation Using a Magnetic Resonance Imaging System. Advanced Science, 2022, , 2105333.	5.6	8
13	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. European Urology, 2022, 81, 407-413.	0.9	41
14	A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided biopsy in the detection of prOstate cancer. PLoS ONE, 2022, 17, e0263345.	1.1	2
15	There Is No Longer a Role for Systematic Biopsies in Prostate Cancer Diagnosis. European Urology Open Science, 2022, 38, 12-13.	0.2	8
16	Deep Learning-Based Long Term Mortality Prediction in the National Lung Screening Trial. IEEE Access, 2022, 10, 34369-34378.	2.6	4
17	Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy. European Urology, 2022, 81, 598-605.	0.9	9
18	Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study. Lancet Oncology, The, 2022, 23, 428-438.	5.1	25

#	Article	IF	Citations
19	Early detection of cancer. Science, 2022, 375, eaay9040.	6.0	291
20	Diagnostic potential of radiological apical tumor involvement. Journal of Robotic Surgery, 2022, , 1.	1.0	1
21	Geographic Variability, Time Trends and Association of Preoperative Magnetic Resonance Imaging with Surgical Outcomes for Elderly United States Men with Prostate Cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Journal of Urology, 2022, 208, 609-617.	0.2	6
22	Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. World Journal of Urology, 2021, 39, 1115-1119.	1.2	23
23	Update on Multiparametric Prostate MRI During Active Surveillance: Current and Future Trends and Role of the PRECISE Recommendations. American Journal of Roentgenology, 2021, 216, 943-951.	1.0	18
24	Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. European Radiology, 2021, 31, 1644-1655.	2.3	37
25	False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naÃ¯ve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. European Urology, 2021, 79, 20-29.	0.9	13
26	Investigating the performance of a novel pH and cathepsin B sensitive, stimulus-responsive nanoparticle for optimised sonodynamic therapy in prostate cancer. Journal of Controlled Release, 2021, 329, 76-86.	4.8	33
27	Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and Quality. Urology, 2021, 148, 316-317.	0.5	1
28	Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still out. BJU International, 2021, 127, 169-170.	1.3	5
29	Role of MRI for the detection of prostate cancer. World Journal of Urology, 2021, 39, 637-649.	1.2	6
30	Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate Cancer and Prostatic Diseases, 2021, 24, 567-574.	2.0	28
31	Re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imagingâ€“targeted Biopsy. Eur Urol Oncol 2020;7:739â€“47. European Urology Oncology, 2021, 4, 127-128.	2.6	0
32	Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer. JAMA Network Open, 2021, 4, e2037657.	2.8	34
33	Re: Simpa S. Salami, Jeffrey J. Tosoian, Srinivas Nallandhighal, et al. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.041. European Urology, 2021, 79, e98-e99.	0.9	1
34	A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological Research. European Urology, 2021, 79, 325-326.	0.9	44
35	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 781.e17-781.e24.	0.8	10
36	Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial. Cancers, 2021, 13, 1985.	1.7	10

#	Article	IF	Citations
37	Tissue-Engineering the Fibrous Pancreatic Tumour Stroma Capsule in 3D Tumouroids to Demonstrate Paclitaxel Response. International Journal of Molecular Sciences, 2021, 22, 4289.	1.8	7
38	3D Cancer Models: The Need for a Complex Stroma, Compartmentalization and Stiffness. Frontiers in Bioengineering and Biotechnology, 2021, 9, 660502.	2.0	58
39	Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer. Journal of Urology, 2021, 205, 1090-1099.	0.2	12
40	Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study. Letter.. Journal of Urology, 2021, 205, 1233-1234.	0.2	0
41	Followup of Men with PI-RADS TM 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.. Journal of Urology, 2021, 205, 1526-1528.	0.2	0
42	Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists. Insights Into Imaging, 2021, 12, 59.	1.6	43
43	Clinical outcomes associated with prostate cancer conspicuity on biparametric and multiparametric MRI: a protocol for a systematic review and meta-analysis of biochemical recurrence following radical prostatectomy. BMJ Open, 2021, 11, e047664.	0.8	1
44	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. Prostate Cancer and Prostatic Diseases, 2021, 24, 1120-1128.	2.0	10
45	Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models. Prostate Cancer and Prostatic Diseases, 2021, 24, 1028-1031.	2.0	10
46	Can quantitative analysis of multi-parametric MRI independently predict failure of focal salvage HIFU therapy in men with radio-recurrent prostate cancer?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 830.e1-830.e8.	0.8	5
47	Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging. European Urology Focus, 2021, 7, 503-505.	1.6	5
48	Outcomes of the RAFT trial: robotic surgery after focal therapy. BJU International, 2021, 128, 504-510.	1.3	8
49	Patient Perspectives and Understanding of MRI-directed Prostate Cancer Diagnosis. Urology, 2021, 153, 6-7.	0.5	0
50	Cellular senescence as a possible link between prostate diseases of the ageing male. Nature Reviews Urology, 2021, 18, 597-610.	1.9	19
51	Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 519-528.	2.6	10
52	Mapping Contemporary Biopsy Zones to Traditional Prostatic Anatomy: The Key to Understanding Relationships Between Prostate Cancer Topography, Magnetic Resonance Imaging Conspicuity, and Clinical Risk. European Urology, 2021, 80, 263-265.	0.9	3
53	Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study. European Urology Open Science, 2021, 30, 16-24.	0.2	4
54	The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature. European Urology Focus, 2021, , .	1.6	8

#	Article	IF	Citations
55	Micro-ultrasound vs. MRI for prostate cancer diagnosis: Considerations to address. Canadian Urological Association Journal, 2021, 15, E522-E523.	0.3	0
56	Computer-aided diagnosis of prostate cancer using multiparametric MRI and clinical features: A patient-level classification framework. Medical Image Analysis, 2021, 73, 102153.	7.0	19
57	An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imagingâ€“based diagnostic pathway with donation of tissue, blood, and urine for biomarker analyses. European Urology, 2021, 80, 398-399.	0.9	1
58	Multiparametric prostate MRI quality assessment using a semi-automated PI-QUAL software program. European Radiology Experimental, 2021, 5, 48.	1.7	17
59	High-Intensity-Focused Ultrasound for Prostate Cancer. , 2021, , 197-213.		0
60	AutoProstate: Towards Automated Reporting of Prostate MRI for Prostate Cancer Assessment Using Deep Learning. Cancers, 2021, 13, 6138.	1.7	10
61	Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis. BMJ Open, 2021, 11, e052277.	0.8	1
62	Re: Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: a prospective study. World Journal of Urology, 2020, 38, 803-804.	1.2	0
63	Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nature Reviews Urology, 2020, 17, 41-61.	1.9	207
64	Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stock. BJU International, 2020, 125, 340-342.	1.3	7
65	Added value of diffusionâ€weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial. BJU International, 2020, 125, 391-398.	1.3	8
66	Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study. European Radiology, 2020, 30, 2082-2090.	2.3	20
67	Magnetic Resonance Imaging Should Be Used in the Active Surveillance of Patients with Localised Prostate Cancer. European Urology, 2020, 77, 318-319.	0.9	10
68	DWI and PRECISE criteria in men on active surveillance for prostate cancer: A multicentre preliminary experience of different ADC calculations. Magnetic Resonance Imaging, 2020, 67, 50-58.	1.0	14
69	Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis. European Urology Open Science, 2020, 20, 37-47.	0.2	27
70	Human airway-like multilayered tissue on 3D-TIPS printed thermoresponsive elastomer/collagen hybrid scaffolds. Acta Biomaterialia, 2020, 113, 177-195.	4.1	15
71	Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial. European Urology Oncology, 2020, 3, 615-619.	2.6	155
72	Reply to Carissa E. Chu, Peter E. Lonergan, and Peter R. Carrollâ€™s Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443â€“51. European Urology, 2020, 78, e112-e113.	0.9	0

#	Article	IF	Citations
73	Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Brigantiâ€™s Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imagingâ€“based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443â€“51. European Urology, 2020, 78, e166.	0.9	0
74	Histopathological features of prostate cancer conspicuity on multiparametric MRI: protocol for a systematic review and meta-analysis. BMJ Open, 2020, 10, e039735.	0.8	0
75	A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists. Scientific Reports, 2020, 10, 17177.	1.6	4
76	Prostate cancer measurements on serial MRI during active surveillance: itâ€™s time to be PRECISE. British Journal of Radiology, 2020, 93, 20200819.	1.0	11
77	Detailing sexual outcomes after treatment of localised prostate cancer with focal therapy using various energy sources: protocol for a mixed-methods study. BMJ Open, 2020, 10, e045500.	0.8	5
78	Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A crossâ€disciplinary translational hypothesis. FASEB Journal, 2020, 34, 14150-14159.	0.2	7
79	What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort. European Urology, 2020, 78, 163-170.	0.9	60
80	The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. European Urology, 2020, 78, 155-160.	0.9	18
81	The anti-angiogenic tyrosine kinase inhibitor Pazopanib kills cancer cells and disrupts endothelial networks in biomimetic three-dimensional renal tumouroids. Journal of Tissue Engineering, 2020, 11, 204173142092059.	2.3	6
82	Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis. BMJ Open, 2020, 10, e034611.	0.8	7
83	Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma. British Journal of Cancer, 2020, 123, 1178-1190.	2.9	51
84	â€œTREXIT 2020â€: why the time to abandon transrectal prostate biopsy starts now. Prostate Cancer and Prostatic Diseases, 2020, 23, 62-65.	2.0	68
85	Evaluation of functional outcomes after a second focal highâ€intensity focused ultrasonography (HIFU) procedure in men with primary localized, nonâ€metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. BJU International, 2020, 125, 853-860.	1.3	23
86	Five-year Outcomes of Magnetic Resonance Imagingâ€“based Active Surveillance for Prostate Cancer: A Large Cohort Study. European Urology, 2020, 78, 443-451.	0.9	94
87	Prostate cancer visibility on multiparametric magnetic resonance imaging: high Gleason grade and increased tumour volume are not the only important histopathological features. BJU International, 2020, 126, 237-239.	1.3	5
88	Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial. Contemporary Clinical Trials, 2020, 93, 105999.	0.8	20
89	Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study. European Urology, 2020, 78, 503-511.	0.9	27
90	An Exploratory Study of Dose Escalation vs Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer. Journal of Endourology, 2020, 34, 641-646.	1.1	7

#	Article	IF	Citations
91	Exploring Patient Views and Acceptance of Multiparametric Magnetic Resonance Imaging for the Investigation of Suspected Prostate Cancer (the PACT Study): A Mixed-Methods Study Protocol. Methods and Protocols, 2020, 3, 26.	0.9	4
92	Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial. Journal of Urology, 2020, 203, 100-107.	0.2	9
93	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy NaÃ¯ve Men: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 203, 1085-1093.	0.2	44
94	Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound. Journal of Urology, 2020, 203, 734-742.	0.2	33
95	Evaluating the Trade-Offs Men with Localized Prostate Cancer Make between the Risks and Benefits of Treatments: The COMPARE Study. Journal of Urology, 2020, 204, 273-280.	0.2	29
96	Reply by Authors. Journal of Urology, 2020, 203, 1093-1093.	0.2	0
97	Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. Journal of Urology, 2020, 204, 1065-1066.	0.2	0
98	MRI in active surveillance: a critical review. Prostate Cancer and Prostatic Diseases, 2019, 22, 5-15.	2.0	36
99	Dropping the <scp>GAD</scp> â€“ just a fad? The case for a simpler, quicker, safer and cheaper prostate <scp>magnetic resonance imaging</scp>. BJU International, 2019, 124, 183-184.	1.3	2
100	Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti's Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review, Meta-analysis. Eur Urol 2019;76:284â€“303. European Urology, 2019, 76, e133-e134.	0.9	0
101	Prediction of significant prostate cancer in biopsy-naÃ¯ve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS. PLoS ONE, 2019, 14, e0221350.	1.1	13
102	Cancer invasion regulates vascular complexity in a three-dimensional biomimetic model. European Journal of Cancer, 2019, 119, 179-193.	1.3	29
103	Salvage Local Treatments After Focal Therapy for Prostate Cancer. European Urology Oncology, 2019, 2, 526-538.	2.6	31
104	Automatic segmentation of prostate MRI using convolutional neural networks: Investigating the impact of network architecture on the accuracy of volume measurement and MRI-ultrasound registration. Medical Image Analysis, 2019, 58, 101558.	7.0	45
105	Exploring the risk-reward balance in focal therapy for prostate cancerâ€"a contribution to the debate. Prostate Cancer and Prostatic Diseases, 2019, 22, 382-384.	2.0	5
106	Acceptability and feasibility study of patient-specific â€˜tumouroidsâ€™ as personalised treatment screening tools: Protocol for prospective tissue and data collection of participants with confirmed or suspected renal cell carcinoma. International Journal of Surgery Protocols, 2019, 14, 24-29.	0.5	4
107	Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2019, 76, 284-303.	0.9	153
108	Stiffness Softening: Thermoresponsive Stiffness Softening of Hierarchically Porous Nanohybrid Membranes Promotes Niches for Mesenchymal Stem Cell Differentiation (Adv. Healthcare Mater.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.0	0

#	Article	IF	Citations
109	Protocol for a feasibility study of a cohort embedded randomised controlled trial comparingNEphronSparingTreatment (NEST) for small renal masses. BMJ Open, 2019, 9, e030965.	0.8	17
110	Targeted biopsy of the prostate: does this result in improvement in detection of highâ€grade cancer or the occurrence of the Will Rogers phenomenon?. BJU International, 2019, 124, 643-648.	1.3	13
111	The Evolution of MRI of the Prostate: The Past, the Present, and the Future. American Journal of Roentgenology, 2019, 213, 384-396.	1.0	39
112	Role of MRI in planning radical prostatectomy: what is the added value?. World Journal of Urology, 2019, 37, 1289-1292.	1.2	26
113	To see or not to see â€" what renders prostate cancer visible?. Nature Reviews Urology, 2019, 16, 274-275.	1.9	0
114	Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. European Urology, 2019, 76, 27-30.	0.9	53
115	VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient. Radiology, 2019, 291, 391-397.	3.6	52
116	Thermoresponsive Stiffness Softening of Hierarchically Porous Nanohybrid Membranes Promotes Niches for Mesenchymal Stem Cell Differentiation. Advanced Healthcare Materials, 2019, 8, e1801556.	3.9	12
117	Development data associated with effects of stiffness softening of 3D-TIPS elastomer nanohybrid scaffolds on tissue ingrowth, vascularization and inflammation in vivo. Data in Brief, 2019, 22, 885-902.	0.5	3
118	Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome. Magnetic Resonance Imaging, 2019, 58, 143-147.	1.0	13
119	Mediumâ€term oncological outcomes in a large cohort of men treated with either focal or hemiâ€ablation using highâ€intensity focused ultrasonography for primary localized prostate cancer. BJU International, 2019, 124, 431-440.	1.3	93
120	Translating costâ€utility modelling into the real world â€" the case of focal highâ€intensity focussed ultrasound and active surveillance. BJU International, 2019, 124, 900-901.	1.3	1
121	Polygenic risk-tailored screening for prostate cancer: A benefitâ€"harm and cost-effectiveness modelling study. PLoS Medicine, 2019, 16, e1002998.	3.9	56
122	Cellular responses to thermoresponsive stiffness memory elastomer nanohybrid scaffolds by 3D-TIPS. Acta Biomaterialia, 2019, 85, 157-171.	4.1	20
123	Sequential prostate MRI reporting in men on active surveillance: initial experience of a dedicated PRECISE software program. Magnetic Resonance Imaging, 2019, 57, 34-39.	1.0	13
124	Prostate cancer heterogeneity: texture analysis score based on multiple magnetic resonance imaging sequences for detection, stratification and selection of lesions at time of biopsy. BJU International, 2019, 124, 76-86.	1.3	18
125	A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI. European Urology, 2019, 75, 203-204.	0.9	16
126	The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification. European Urology, 2019, 75, 733-740.	0.9	67

#	Article	IF	Citations
127	Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84â€“91. European Urology, 2019, 75, e21-e22.	0.9	2
128	Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE): a prospective cohort validating study assessing Prostate HistoScanning. Prostate Cancer and Prostatic Diseases, 2019, 22, 261-267.	2.0	9
129	Management of Radiologically Indeterminate Magnetic Resonance Imaging Signals in Men at Risk of Prostate Cancer. European Urology Focus, 2019, 5, 62-68.	1.6	9
130	Prostate Indeterminate Lesions on Magnetic Resonance Imagingâ€”Biopsy Versus Surveillance: A Literature Review. European Urology Focus, 2019, 5, 799-806.	1.6	27
131	Conditional Segmentation in Lieu of Image Registration. Lecture Notes in Computer Science, 2019, , 401-409.	1.0	8
132	Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results. Journal of Urology, 2019, 201, 315-321.	0.2	19
133	Title is missing!. , 2019, 16, e1002998.		0
134	Title is missing!. , 2019, 16, e1002998.		0
135	Title is missing!. , 2019, 16, e1002998.		0
136	Title is missing!. , 2019, 16, e1002998.		0
137	Technical Note: Error metrics for estimating the accuracy of needle/instrument placement during transperineal magnetic resonance/ultrasoundâ€guided prostate interventions. Medical Physics, 2018, 45, 1408-1414.	1.6	7
138	Re: Jochen Walz. The â€œPROMISâ€•of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31â€“2. European Urology, 2018, 73, e151-e152.	0.9	0
139	Has tailored, tissueâ€selective tumour ablation in men with prostate cancer come of age?. BJU International, 2018, 121, 676-677.	1.3	1
140	Phenotypic appearances of prostate utilizing PET-MRI and PET-CT with 68Ga-PSMA, radiolabelled choline and 68Ga-DOTATATE. Nuclear Medicine Communications, 2018, 39, 196-204.	0.5	2
141	The CADMUS trial â€“ Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer. Contemporary Clinical Trials, 2018, 66, 86-92.	0.8	9
142	A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 67-76.	0.8	19
143	Performance characteristics of multiparametric-MRI at a non-academic hospital using transperineal template mapping biopsy as a reference standard. International Journal of Surgery Open, 2018, 10, 66-71.	0.2	2
144	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 2018, 378, 1767-1777.	13.9	2,036

#	Article	IF	Citations
145	Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). European Urology, 2018, 73, 23-30.	0.9	133
146	Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 13.e1-13.e10.	0.8	11
147	The British Urology Researchers in Surgical Training (<scp>BURST</scp>) Research Collaborative: an alternative research model for carrying out large scale multiâ€centre urological studies. BJU International, 2018, 121, 6-9.	1.3	13
148	Prostate cancer detection using quantitative T₂ and T₂â€weighted imaging: The effects of 5â€alphaâ€reductase inhibitors in men on active surveillance. Journal of Magnetic Resonance Imaging, 2018, 47, 1646-1653.	1.9	12
149	Multiparametric prostate MRI: technical conduct, standardized report and clinical use. Minerva Urology and Nephrology, 2018, 70, 9-21.	1.3	20
150	Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer. Oncotarget, 2018, 9, 12812-12824.	0.8	8
151	Data of a stiffness softening mechanism effect on proliferation and differentiation of a human bone marrow derived mesenchymal stem cell line towards the chondrogenic and osteogenic lineages. Data in Brief, 2018, 21, 133-142.	0.5	0
152	Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK. BMJ Open, 2018, 8, e024941.	0.8	14
153	Stiffness memory nanohybrid scaffolds generated by indirect 3D printing for biologically responsive soft implants. Acta Biomaterialia, 2018, 80, 188-202.	4.1	22
154	Stiffness memory of indirectly 3D-printed elastomer nanohybrid regulates chondrogenesis and osteogenesis of human mesenchymal stem cells. Biomaterials, 2018, 186, 64-79.	5.7	46
155	Patient Reported Outcome Measures for Transperineal Template Prostate Mapping Biopsies in the PICTURE Study. Journal of Urology, 2018, 200, 1235-1240.	0.2	55
156	Label-driven weakly-supervised learning for multimodal deformarle image registration. , 2018, , .		67
157	A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. European Urology, 2018, 74, 422-429.	0.9	220
158	Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRIâ€characterized prostates. Prostate, 2018, 78, 1229-1237.	1.2	9
159	The natural history of prostate cancer on MRI: lessons from an active surveillance cohort. Prostate Cancer and Prostatic Diseases, 2018, 21, 556-563.	2.0	13
160	Weakly-supervised convolutional neural networks for multimodal image registration. Medical Image Analysis, 2018, 49, 1-13.	7.0	280
161	Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness. Journal of Urology, 2018, 200, 786-793.	0.2	65
162	Accuracy of Transperineal Targeted Prostate Biopsies, Visual Estimation and Image Fusion in Men Needing Repeat Biopsy in the PICTURE Trial. Journal of Urology, 2018, 200, 1227-1234.	0.2	38

#	Article	IF	Citations
163	MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years. Prostate Cancer and Prostatic Diseases, 2018, 21, 473-487.	2.0	42
164	MRI-Targeted Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 2018, 379, 589-590.	13.9	59
165	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. BJU International, 2018, 122, 970-977.	1.3	17
166	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. Health Technology Assessment, 2018, 22, 1-176.	1.3	70
167	Development and Phantom Validation of a 3-D-Ultrasound-Guided System for Targeting MRI-Visible Lesions During Transrectal Prostate Biopsy. IEEE Transactions on Biomedical Engineering, 2017, 64, 946-958.	2.5	14
168	Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet, The, 2017, 389, 815-822.	6.3	2,267
169	Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 150.e1-150.e7.	0.8	37
170	Is a negative prostate biopsy a risk factor for a prostate cancer related death?. Lancet Oncology, The, 2017, 18, 162-163.	5.1	7
171	Focal salvage highâ€intensity focused ultrasound in radiorecurrent prostate cancer. BJU International, 2017, 120, 246-256.	1.3	39
172	A comparison of Bayesian and non-linear regression methods for robust estimation of pharmacokinetics in DCE-MRI and how it affects cancer diagnosis. Computerized Medical Imaging and Graphics, 2017, 56, 1-10.	3.5	18
173	Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e188.	5.1	10
174	The changing prostate cancer pathway â€“ new challenges, new pitfalls. Medico-Legal Journal, 2017, 85, 70-80.	0.2	0
175	The role of the multiparametric MRI in the diagnosis of prostate cancer in biopsy-naÃ¯ve men. Current Opinion in Urology, 2017, 27, 488-494.	0.9	15
176	An end to the phenomenon of â€˜upgradingâ€™ in early prostate cancer?. BJU International, 2017, 119, 506-507.	1.3	2
177	The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. British Journal of Cancer, 2017, 116, 1159-1165.	2.9	90
178	Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncology, The, 2017, 18, 181-191.	5.1	263
179	A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. BMJ Open, 2017, 7, e017863.	0.8	14
180	Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds toÂCorrelate Images with Whole Mount Pathology. Journal of Urology, 2017, 198, 1436-1437.	0.2	1

#	Article	IF	Citations
181	MP33-20 THE SMARTTARGET BIOPSY TRIAL: A PROSPECTIVE PAIRED BLINDED TRIAL WITH RANDOMISATION TO COMPARE VISUAL-ESTIMATION AND IMAGE-FUSION TARGETED PROSTATE BIOPSIES. Journal of Urology, 2017, 197, .	0.2	4
182	Diagnostic accuracy of the PROMIS study â€“ Authorsâ€™ reply. Lancet, The, 2017, 390, 362.	6.3	5
183	MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial. European Radiology, 2017, 27, 4767-4774.	2.3	24
184	Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensityâ€“focused ultrasound focal therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 30.e9-30.e15.	0.8	65
185	The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPEDâ€”A Randomized, Placebo Controlled, Double-Blind Clinical Trial. Journal of Urology, 2017, 197, 1006-1013.	0.2	19
186	â€œTextural analysis of multiparametric MRI detects transition zone prostate cancerâ€• European Radiology, 2017, 27, 2348-2358.	2.3	74
187	New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. European Urology, 2017, 71, 17-34.	0.9	232
188	Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer. Journal of Urology, 2017, 197, 647-654.	0.2	66
189	Editorial Comment. Journal of Urology, 2016, 196, 559-559.	0.2	0
190	Reply from Authors re: Giorgio Gandaglia, Alberto Briganti, Andrea Salonia, Francesco Montorsi. Excellent Erectile Function Recovery after Focal Therapy: Is This Enough? Eur Urol 2016;69:852â€“3. European Urology, 2016, 69, 853-854.	0.9	2
191	Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy. Radiotherapy and Oncology, 2016, 119, 104-110.	0.3	10
192	The next level of 3D tumour models: immunocompetence. Drug Discovery Today, 2016, 21, 1421-1428.	3.2	25
193	¹⁸F-FECH PET/CT to Assess Clinically Significant Disease in Prostate Cancer: Correlation With Maximum and Total Cancer Core Length Obtained via MRI-Guided Template Mapping Biopsies. American Journal of Roentgenology, 2016, 207, 1297-1306.	1.0	1
194	From computer-assisted intervention research to clinical impact: The need for a holistic approach. Medical Image Analysis, 2016, 33, 72-78.	7.0	7
195	Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. Journal of Urology, 2016, 196, 1096-1104.	0.2	51
196	The challenging landscape of medical device approval in localized prostate cancer. Nature Reviews Urology, 2016, 13, 91-98.	1.9	5
197	Doubling our precision of risk stratification in early prostate cancer: too good to be true?. BJU International, 2016, 117, 8-9.	1.3	1
198	Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort. European Urology, 2016, 70, 668-674.	0.9	56

#	Article	IF	Citations
199	Incidental prostate cancer diagnosed following a transurethral resection of the prostate: A national database analysis in England. Journal of Clinical Urology, 2016, 9, 170-176.	0.1	4
200	Evidence based management of male lower urinary tract symptoms: A contemporary update. International Journal of Surgery, 2016, 25, 162-163.	1.1	0
201	The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials. European Urology, 2016, 69, 844-851.	0.9	47
202	Repeat Prostate Biopsy: Rationale, Indications, and Strategies. European Urology Focus, 2015, 1, 127-136.	1.6	12
203	Determination of optimal drug dose and light doseÂindex to achieve minimally invasive focal ablation of localised prostate cancer using <scp>WST</scp>11â€vascularâ€targeted photodynamic (<scp>VTP</scp>) therapy. BJU International, 2015, 116, 888-896.	1.3	81
204	The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update. European Urology Focus, 2015, 1, 212-214.	1.6	0
205	Are men who are biopsied without prior prostate magnetic resonance imaging getting substandard care?. BJU International, 2015, 116, 837-839.	1.3	3
206	A review of economic evaluations of diagnostic strategies using imaging in men at risk of prostate cancer. Current Opinion in Urology, 2015, 25, 483-489.	0.9	15
207	Identifying the Index Lesion with Template Prostate Mapping Biopsies. Journal of Urology, 2015, 193, 1185-1190.	0.2	16
208	Focal Therapy: Patients, Interventions, and Outcomesâ€"A Report from a Consensus Meeting. European Urology, 2015, 67, 771-777.	0.9	206
209	Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. European Urology, 2015, 68, 1045-1053.	0.9	657
210	A randomized controlled trial to investigate magnetic resonance imagingâ€"targeted biopsy as an alternative diagnostic strategy to transrectal ultrasoundâ€"guided prostate biopsy in the diagnosis of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 156-157.	0.8	0
211	Why Focal Therapy is a Legitimate and Necessary Response to a Changing World. Journal of Urology, 2015, 194, 875-876.	0.2	5
212	What Burden of Prostate Cancer Can Radiologists Rule Out on Multiparametric Magnetic Resonance Imaging? A Sensitivity Analysis Based on Varying the Target Condition in Template Prostate Mapping Biopsies. Urology, 2015, 86, 544-551.	0.5	2
213	Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 424.e9-424.e16.	0.8	44
214	Evaluating variation in use of definitive therapy and risk-adjusted prostate cancer mortality in England and the USA. BMJ Open, 2015, 5, e006805-e006805.	0.8	3
215	Histological outcomes after focal high-intensity focused ultrasound and cryotherapy. World Journal of Urology, 2015, 33, 955-964.	1.2	30
216	Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 787-793.	0.4	30

#	Article	IF	Citations
217	Focal Therapy of Prostate Cancer Using Irreversible Electroporation. Techniques in Vascular and Interventional Radiology, 2015, 18, 147-152.	0.4	13
218	Population-based prediction of subject-specific prostate deformation for MR-to-ultrasound image registration. Medical Image Analysis, 2015, 26, 332-344.	7.0	33
219	Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. European Urology, 2015, 68, 927-936.	0.9	163
220	Logistic regression model for diagnosis of transition zone prostate cancer on multi-parametric MRI. European Radiology, 2015, 25, 523-532.	2.3	40
221	Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imagingâ€“Ultrasound Fusion Targeted Biopsy: A Systematic Review. European Urology, 2015, 68, 8-19.	0.9	381
222	A novel randomised controlled trial design in prostate cancer. BJU International, 2015, 116, 6-8.	1.3	4
223	Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis. BMJ Open, 2014, 4, e004895-e004895.	0.8	23
224	Management of low risk prostate cancer. Current Opinion in Urology, 2014, 24, 270-279.	0.9	24
225	Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study. European Urology, 2014, 65, 628-634.	0.9	55
226	The PICTURE study â€" Prostate Imaging (multi-parametric MRI and Prostate HistoScanningâ„¢) Compared to Transperineal Ultrasound guided biopsy for significant prostate cancer Risk Evaluation. Contemporary Clinical Trials, 2014, 37, 69-83.	0.8	50
227	Is Prostate Magnetic Resonance Imaging Going to Break the Bank?. European Urology, 2014, 66, 437-438.	0.9	6
228	The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review. European Urology, 2014, 66, 732-751.	0.9	298
229	The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA levelâ€"Can it rule out clinically significant prostate cancer?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 45.e17-45.e22.	0.8	110
230	Salvage High-intensity Focused Ultrasound for Patients With Recurrent Prostate Cancer After Brachytherapy. Urology, 2014, 84, 1157-1162.	0.5	27
231	Re: Jarow et al.: Drug and Device Development for Localized Prostate Cancer: Report of a Food and Drug Administration/American Urological Association Public Workshop (Urology 2014;83:975-979). Urology, 2014, 84, 732-733.	0.5	3
232	Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?11Mohamed Abd-Alazeez receives funding from the Egyptian government. Mark Emberton and Hashim U. Ahmed receive funding from USHIFU and Advanced Medical Diagnostics for clinical trials. Mark Emberton is a paid consultant for Steba Biotech, USHIFU and Sanofi-Aventis. Mark Emberton has received research support by GSK for a study evaluating the role of MRI in men with prostate. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 741-747.	0.8	27
233	Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncology, The, 2014, 15, e404-e414.	5.1	196
234	A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Contemporary Clinical Trials, 2014, 39, 57-65.	0.8	53

#	Article	IF	Citations
235	Can we deliver randomized trials of focal therapy in prostate cancer?. Nature Reviews Clinical Oncology, 2014, 11, 482-491.	12.5	60
236	Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy. European Urology, 2014, 66, 12-19.	0.9	35
237	Defining the level of evidence for technology adoption in the localized prostate cancer pathway. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 924-930.	0.8	7
238	Management of low risk prostate cancerâ€"active surveillance and focal therapy. Nature Reviews Clinical Oncology, 2014, 11, 324-334.	12.5	61
239	Systematic Review of Complications of Prostate Biopsy. European Urology, 2013, 64, 876-892.	0.9	779
240	Are we ready for the new wave of focal therapy interventions for men with early prostate cancer?. BJU International, 2013, 112, 423-424.	1.3	1
241	Image-Guided Prostate Biopsy Using Magnetic Resonance Imagingâ€"Derived Targets: A Systematic Review. European Urology, 2013, 63, 125-140.	0.9	479
242	Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient Care. European Urology, 2013, 63, 214-230.	0.9	214
243	Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. Journal of Magnetic Resonance Imaging, 2013, 37, 48-58.	1.9	119
244	Has Magnetic Resonanceâ€"Guided Biopsy of the Prostate Become the Standard of Care?. European Urology, 2013, 64, 720-721.	0.9	14
245	Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. European Urology, 2013, 64, 544-552.	0.9	383
246	Transperineal Magnetic Resonance Image Targeted Prostate Biopsy Versus Transperineal Template Prostate Biopsy in the Detection of Clinically Significant Prostate Cancer. Journal of Urology, 2013, 189, 860-866.	0.2	181
247	<scp>TOOKAD</scp>^{Â®}<scp>S</scp>oluble vascularâ€targeted photodynamic (<scp>VTP</scp>) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU International, 2013, 112, 766-774.	1.3	135
248	The role of MRI in active surveillance of prostate cancer. Current Opinion in Urology, 2013, 23, 261-267.	0.9	28
249	Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncology, The, 2012, 13, 622-632.	5.1	359
250	Identifying Candidates for Active Surveillance: An Evaluation of the Repeat Biopsy Strategy for Men with Favorable Risk Prostate Cancer. Journal of Urology, 2012, 188, 762-768.	0.2	86
251	Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy. Cancer, 2012, 118, 4148-4155.	2.0	83
252	Foreword. BJU International, 2012, 109, v-v.	1.3	0

#	Article	IF	Citations
253	MR to ultrasound registration for image-guided prostate interventions. Medical Image Analysis, 2012, 16, 687-703.	7.0	148
254	Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU International, 2012, 109, 1636-1647.	1.3	103
255	Multiparametric magnetic resonance imaging in the diagnosis and characterisation of prostate cancer: The PROMIS study.. Journal of Clinical Oncology, 2012, 30, 62-62.	0.8	1
256	Characterizing Clinically Significant Prostate Cancer Using Template Prostate Mapping Biopsy. Journal of Urology, 2011, 186, 458-464.	0.2	253
257	The influence of family history on prostate cancer risk: implications for clinical management. BJU International, 2011, 107, 716-721.	1.3	28
258	Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU International, 2011, 107, 876-880.	1.3	27
259	Modelling Prostate Motion for Data Fusion During Image-Guided Interventions. IEEE Transactions on Medical Imaging, 2011, 30, 1887-1900.	5.4	46
260	Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting. European Urology, 2011, 59, 477-494.	0.9	642
261	Combination therapyâ€"a strategy for BPH-related progression. Nature Reviews Urology, 2010, 7, 239-240.	1.9	0
262	SCREENING FOR PROSTATE CANCER APPEARS TO WORK, BUT AT WHAT COST?. BJU International, 2009, 104, 290-292.	1.3	5
263	Is it time to consider a role for MRI before prostate biopsy?. Nature Reviews Clinical Oncology, 2009, 6, 197-206.	12.5	288
264	Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU International, 2008, 102, 981-986.	1.3	43
265	Prostate Cancer Staging Tablesâ€"A Predictive Model for the UK. British Journal of Medical and Surgical Urology, 2008, 1, 107-119.	0.2	1
266	Treating coexistent benign prostatic hyperplasia/lower urinary tract symptoms and erectile dysfunction in the aging male. Aging Health, 2007, 3, 191-200.	0.3	0
267	Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. BJU International, 2007, 100, 249-253.	1.3	30
268	Response to Daily 10 Mg Alfuzosin Predicts Acute Urinary Retention and Benign Prostatic Hyperplasia Related Surgery in Men With Lower Urinary Tract Symptoms. Journal of Urology, 2006, 176, 1051-1056.	0.2	13
269	How Good is MRI at Detecting and Characterising Cancer within the Prostate?. European Urology, 2006, 50, 1163-1175.	0.9	319
270	Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology, 2005, 66, 316-322.	0.5	33

#	Article	IF	Citations
271	Photodynamic Therapy for Prostate Cancer Recurrence After Radiotherapy: A Phase I Study. Journal of Urology, 2002, 168, 1427-1432.	0.2	183